155 related articles for article (PubMed ID: 20594194)
1. Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release.
Sato A; Tamura Y; Sato N; Yamashita T; Takada T; Sato M; Osai Y; Okura M; Ono I; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
Cancer Sci; 2010 Sep; 101(9):1939-46. PubMed ID: 20594194
[TBL] [Abstract][Full Text] [Related]
2. N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.
Sato M; Yamashita T; Ohkura M; Osai Y; Sato A; Takada T; Matsusaka H; Ono I; Tamura Y; Sato N; Sasaki Y; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
J Invest Dermatol; 2009 Sep; 129(9):2233-41. PubMed ID: 19295615
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.
Takada T; Yamashita T; Sato M; Sato A; Ono I; Tamura Y; Sato N; Miyamoto A; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
J Biomed Biotechnol; 2009; 2009():457936. PubMed ID: 19830247
[TBL] [Abstract][Full Text] [Related]
4. T-cell receptor repertoires of tumor-infiltrating lymphocytes after hyperthermia using functionalized magnetite nanoparticles.
Ito A; Yamaguchi M; Okamoto N; Sanematsu Y; Kawabe Y; Wakamatsu K; Ito S; Honda H; Kobayashi T; Nakayama E; Tamura Y; Okura M; Yamashita T; Jimbow K; Kamihira M
Nanomedicine (Lond); 2013 Jun; 8(6):891-902. PubMed ID: 23066648
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation of Melanoma by Chemo-Thermo-Immunotherapy Using Conjugates of Melanogenesis Substrate NPrCAP and Magnetite Nanoparticles: A Review.
Tamura Y; Ito A; Wakamatsu K; Kamiya T; Torigoe T; Honda H; Yamashita T; Uhara H; Ito S; Jimbow K
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742905
[TBL] [Abstract][Full Text] [Related]
6. Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.
Jimbow K; Ishii-Osai Y; Ito S; Tamura Y; Ito A; Yoneta A; Kamiya T; Yamashita T; Honda H; Wakamatsu K; Murase K; Nohara S; Nakayama E; Hasegawa T; Yamamoto I; Kobayashi T
J Skin Cancer; 2013; 2013():742925. PubMed ID: 23533767
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models.
Ito S; Nishigaki A; Ishii-Osai Y; Ojika M; Wakamatsu K; Yamashita T; Tamura Y; Ito A; Honda H; Nakayama E; Jimbow K
Biochem Pharmacol; 2012 Sep; 84(5):646-53. PubMed ID: 22728921
[TBL] [Abstract][Full Text] [Related]
9. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermia enhances CTL cross-priming.
Shi H; Cao T; Connolly JE; Monnet L; Bennett L; Chapel S; Bagnis C; Mannoni P; Davoust J; Palucka AK; Banchereau J
J Immunol; 2006 Feb; 176(4):2134-41. PubMed ID: 16455969
[TBL] [Abstract][Full Text] [Related]
11. Targeting to static endosome is required for efficient cross-presentation of endoplasmic reticulum-resident oxygen-regulated protein 150-peptide complexes.
Kutomi G; Tamura Y; Okuya K; Yamamoto T; Hirohashi Y; Kamiguchi K; Oura J; Saito K; Torigoe T; Ogawa S; Hirata K; Sato N
J Immunol; 2009 Nov; 183(9):5861-9. PubMed ID: 19812200
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.
Ito A; Matsuoka F; Honda H; Kobayashi T
Cancer Immunol Immunother; 2004 Jan; 53(1):26-32. PubMed ID: 14551746
[TBL] [Abstract][Full Text] [Related]
13. 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma.
Ito A; Fujioka M; Yoshida T; Wakamatsu K; Ito S; Yamashita T; Jimbow K; Honda H
Cancer Sci; 2007 Mar; 98(3):424-30. PubMed ID: 17270032
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol.
Tandon M; Thomas PD; Shokravi M; Singh S; Samra S; Chang D; Jimbow K
Biochem Pharmacol; 1998 Jun; 55(12):2023-9. PubMed ID: 9714323
[TBL] [Abstract][Full Text] [Related]
15. Surface expression of a C-terminal alpha-helix region in heat shock protein 72 on murine LL/2 lung carcinoma can be recognized by innate immune sentinels.
Tani F; Ohno M; Furukawa Y; Sakamoto M; Masuda S; Kitabatake N
Mol Immunol; 2009 Apr; 46(7):1326-39. PubMed ID: 19157555
[TBL] [Abstract][Full Text] [Related]
16. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
17. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
18. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.
Werthmöller N; Frey B; Rückert M; Lotter M; Fietkau R; Gaipl US
Int J Hyperthermia; 2016; 32(1):23-30. PubMed ID: 26754406
[TBL] [Abstract][Full Text] [Related]
19. Cancer hyperthermia using magnetic nanoparticles.
Kobayashi T
Biotechnol J; 2011 Nov; 6(11):1342-7. PubMed ID: 22069094
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with trifunctional nanoparticles that address CD8
Shen L; Krauthäuser S; Fischer K; Hobernik D; Abassi Y; Dzionek A; Nikolaev A; Voltz N; Diken M; Krummen M; Montermann E; Tubbe I; Lorenz S; Strand D; Schild H; Grabbe S; Bros M
Nanomedicine (Lond); 2016 Oct; 11(20):2647-2662. PubMed ID: 27628310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
